8-K: LifeVantage Reports Improved Profitability Despite Revenue Dip in Second Quarter of Fiscal 2024

LifeVantage Corporation announced a decrease in revenue but a significant improvement in profitability for the second quarter of fiscal year 2024, driven by its LV360 initiatives and strong sales of its TrueScience Liquid Collagen product.

Summary

• LifeVantage Corporation reported a revenue of $51.6 million for the second quarter of fiscal year 2024, which is a 3.8% decrease compared to the same period last year.
• Excluding the impact of foreign currency fluctuations, the revenue decrease was approximately 3.4%.
• Revenue in the Americas decreased by 1.6%, while revenue in Asia/Pacific & Europe decreased by 10.0%, or 8.0% on a constant currency basis.
• The company's net loss per diluted share improved to $0.05, compared to a net loss of $0.08 per diluted share in the prior year.
• Adjusted earnings per diluted share was $0.10, a significant improvement from an adjusted loss per share of $0.07 in the same quarter last year.
• Adjusted EBITDA increased by 289.0% to $3.1 million.
• Gross profit margin improved to 78.6% of revenue, up from 78.1% in the prior year, due to price increases, higher shipping revenues, and changes in product mix.
• The company generated $6.5 million in cash from operations during the first six months of fiscal 2024, compared to using $0.4 million in the same period last year.
• LifeVantage repurchased 0.3 million shares of its common stock for $1.9 million during the quarter.
• A cash dividend of $0.035 per common share was declared, payable on March 15, 2024, to shareholders of record on March 1, 2024.
• The company revised its full-year revenue guidance to $207 million to $213 million, down from the previous range of $216 million to $226 million, but increased its adjusted EBITDA guidance to $16 million to $18 million and adjusted earnings per share to $0.57 to $0.67.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the significant improvement in profitability and adjusted EBITDA, despite a slight revenue decline and reduced full year revenue guidance. The company's strategic initiatives appear to be gaining traction, but there are still challenges to overcome.

Positives

• The company demonstrated significant year-over-year improvement in profitability.
• Adjusted EBITDA saw a substantial increase, indicating improved operational efficiency.
• The TrueScience Liquid Collagen product line experienced strong sales growth.
• The LV360 initiatives are gaining traction and contributing to improved performance.
• The company has a strong cash position with $17.3 million in cash and cash equivalents and no debt.
• The company declared a cash dividend of $0.035 per common share.
• The company increased its adjusted EBITDA and adjusted earnings per share guidance for the full year.

Negatives

• Overall revenue decreased by 3.8% compared to the same quarter last year.
• Revenue in the Asia/Pacific & Europe region experienced a significant decline of 10.0%.
• The company revised its full-year revenue guidance downwards.
• The number of active independent consultants and customers decreased year-over-year.

Risks

• The company faces challenges in maintaining revenue growth, particularly in the Asia/Pacific & Europe region.
• Fluctuations in foreign currency exchange rates continue to negatively impact revenue.
• The company's future performance is subject to risks and uncertainties, including those related to the global economic environment and the impact of COVID-19.
• The company's forward-looking statements are not guarantees of performance and actual results could differ materially.

Future Outlook

The company expects to generate revenue in the range of $207 million to $213 million in fiscal year 2024 and adjusted EBITDA of $16 million to $18 million, with adjusted earnings per share in the range of $0.57 to $0.67. The company expects a full year tax rate of approximately 22% to 24%.

Management Comments

• We delivered significant year-over-year improvement in profitability during the second quarter as our LV360 initiatives continued to gain traction, said Steve Fife, President and Chief Executive Officer of Life Vantage.
• Our latest results further demonstrate the effectiveness of LV360 to improve performance and drive value for stockholders.

Industry Context

LifeVantage operates in the health and wellness industry, which is experiencing growth, but also faces competition. The company's focus on nutrigenomics and direct selling positions it within a niche market. The results indicate that while the company is improving profitability, it is facing challenges in maintaining revenue growth, which is a common issue in the direct selling industry.

Comparison to Industry Standards

• LifeVantage's revenue decline of 3.8% contrasts with some direct selling companies that have seen growth, such as Herbalife which reported a 2.5% increase in net sales in their most recent quarter, and Nu Skin which reported a 1% increase in revenue.
• The 289% increase in adjusted EBITDA is a significant improvement, and is better than many of its peers in the direct selling industry, which have seen more modest improvements in profitability.
• The company's gross profit margin of 78.6% is relatively high compared to some competitors, such as USANA which reported a gross profit margin of 77.5% in their most recent quarter, indicating strong pricing power and cost management.
• The company's focus on nutrigenomics is a differentiator, but it also faces competition from companies with broader product portfolios.

Stakeholder Impact

• Shareholders will benefit from the increased profitability and the declared cash dividend.
• Employees may see positive impacts from the company's improved financial performance.
• Customers will continue to have access to the company's health and wellness products.
• Suppliers may see continued business with the company.

Next Steps

• The company will continue to implement its LV360 transformation plan.
• The Evolve compensation plan and Rewards Circle loyalty program will be rolled out to Mexico, Canada, and Europe in February.
• The company will hold an investor conference call to discuss the results.

Key Dates

Keywords

LifeVantage, LV360, TrueScience Liquid Collagen, EBITDA, Revenue, Profitability, Nutrigenomics, Direct Selling, Dividend, Financial Results